Some bacteria do not defeat antibiotics by evolving resistance right away—they outlast treatment by slipping into ...

Secukinumab demonstrated a 72.7% persistence rate at one year, indicating strong long-term management potential for moderate to severe psoriasis. The study involved 88 patients, with a mean baseline ...

A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable differences in treatment patterns, discontinuation rates, persistence, and ...